World's Best Scientists 2026 revealed!
Award Badge
Immunology
USA
2026

D-Index & Metrics

Best Scientists

D-Index
166
Citations
115487
World Ranking
1001
National Ranking
593

Immunology

D-Index
167
Citations
120432
World Ranking
60
National Ranking
42

Medicine

D-Index
167
Citations
120444
World Ranking
583
National Ranking
339

Nicholas P. Restifo publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Nicholas P. Restifo sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 476 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Nicholas P. Restifo D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Nicholas P. Restifo sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 167 D-Index — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Immunology in United States Leader Award
  • 2025 - Research.com Immunology in United States Leader Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Immune system
  • Cancer

Nicholas P. Restifo spends much of his time researching Immunology, Cytotoxic T cell, Antigen, Immunotherapy and T cell. His work deals with themes such as Cancer and Cancer research, Melanoma, which intersect with Immunology. His studies deal with areas such as Molecular biology, CD8 and Cytokine as well as Cytotoxic T cell.

His Antigen research includes elements of Antibody and Virology. His work on Cancer immunotherapy and Cancer vaccine as part of general Immunotherapy study is frequently linked to Natural selection, therefore connecting diverse disciplines of science. Nicholas P. Restifo combines subjects such as Interleukin 2 and Dendritic cell with his study of T cell.

His most cited work include:

  • Cancer immunotherapy: moving beyond current vaccines. (2543 citations)
  • Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes (2452 citations)
  • Cancer regression in patients after transfer of genetically engineered lymphocytes (2174 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Immunology, Immunotherapy, T cell, Cytotoxic T cell and Antigen. Nicholas P. Restifo interconnects Cancer research and Melanoma in the investigation of issues within Immunology. His Cancer research study combines topics in areas such as Interleukin 12 and Cytokine.

His Immunotherapy research is multidisciplinary, relying on both Interleukin 2 and Oncology. In his study, Cellular differentiation is strongly linked to Cell biology, which falls under the umbrella field of T cell. His biological study spans a wide range of topics, including Molecular biology and Virology.

He most often published in these fields:

  • Immunology (56.89%)
  • Immunotherapy (32.00%)
  • T cell (30.89%)

What were the highlights of his more recent work (between 2014-2021)?

  • T cell (30.89%)
  • Cancer research (28.67%)
  • Immunotherapy (32.00%)

In recent papers he was focusing on the following fields of study:

Nicholas P. Restifo mainly focuses on T cell, Cancer research, Immunotherapy, Immunology and Adoptive cell transfer. The study incorporates disciplines such as Cell biology, Effector, CD8 and Cytokine in addition to T cell. His CD8 research is multidisciplinary, incorporating perspectives in Cytotoxic T cell and Tyrosine kinase.

The concepts of his Immunotherapy study are interwoven with issues in Melanoma, Oncology and Antigen. The Immunology study combines topics in areas such as Reprogramming and Disease. He has researched Adoptive cell transfer in several fields, including Antibody, Tumor-infiltrating lymphocytes, Cell therapy and Interleukin 15.

Between 2014 and 2021, his most popular works were:

  • Adoptive cell transfer as personalized immunotherapy for human cancer. (1238 citations)
  • A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response (412 citations)
  • Identification of essential genes for cancer immunotherapy (370 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Immune system
  • Cancer

His scientific interests lie mostly in Immunotherapy, Immunology, T cell, Cancer research and Adoptive cell transfer. Immunology is closely attributed to Cancer in his work. Nicholas P. Restifo has included themes like Epigenetics, CD8 and Cell biology in his T cell study.

He combines subjects such as Tumor microenvironment, Cytotoxic T cell and Chromatin with his study of CD8. His Cancer research research is multidisciplinary, incorporating elements of Effector, Cancer immunotherapy and T-cell receptor. His biological study spans a wide range of topics, including Oncology, Antigen, Internal medicine, Melanoma and Gene.

Best Publications

  • Cancer regression in patients after transfer of genetically engineered lymphocytes

    Richard A. Morgan;Mark E. Dudley;John R. Wunderlich;Marybeth S. Hughes

  • Cancer immunotherapy: moving beyond current vaccines.

    Steven A Rosenberg;James C Yang;Nicholas P Restifo

  • Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

    Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  • Adoptive cell transfer as personalized immunotherapy for human cancer.

    Steven A. Rosenberg;Nicholas P. Restifo

  • Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy

    Steven A. Rosenberg;James C. Yang;Richard M. Sherry;Udai S. Kammula

  • Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

    Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  • A human memory T cell subset with stem cell-like properties

    Luca Gattinoni;Enrico Lugli;Yun Ji;Zoltan Pos

  • Adoptive cell transfer: a clinical path to effective cancer immunotherapy

    Steven A. Rosenberg;Nicholas P. Restifo;James C. Yang;Richard A. Morgan

  • Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

    Mark E. Dudley;John R. Wunderlich;James C. Yang;Richard M. Sherry

  • Adoptive immunotherapy for cancer: harnessing the T cell response

    Nicholas P. Restifo;Mark E. Dudley;Steven A. Rosenberg

  • Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

    Paul F. Robbins;Richard A. Morgan;Steven A. Feldman;James C. Yang

  • Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

    Giao Q. Phan;James C. Yang;Richard M. Sherry;Patrick Hwu

  • Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

    Laura A. Johnson;Richard A. Morgan;Mark E. Dudley;Lydie Cassard

  • Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

    Mark E. Dudley;James C. Yang;Richard Sherry;Marybeth S. Hughes

  • Adoptive immunotherapy for cancer: building on success.

    Luca Gattinoni;Daniel J. Powell;Steven A. Rosenberg;Nicholas P. Restifo

  • Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

    Richard A. Morgan;Nachimuthu Chinnasamy;Daniel Abate-Daga;Alena Gros

  • Defining ‘T cell exhaustion’

    Christian U Blank;W Nicholas Haining;Werner Held;Patrick G Hogan;Patrick G Hogan

  • Natural selection of tumor variants in the generation of “tumor escape” phenotypes

    Hung T. Khong;Nicholas P. Restifo

  • Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

    Luca Gattinoni;Steven E. Finkelstein;Christopher A. Klebanoff;Christopher A. Klebanoff;Paul A. Antony

  • Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

    Christopher A. Klebanoff;Luca Gattinoni;Parizad Torabi-Parizi;Keith Kerstann

  • T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

    Maria R. Parkhurst;James C. Yang;Russell C. Langan;Mark E. Dudley

  • Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

    Luca Gattinoni;Christopher A. Klebanoff;Christopher A. Klebanoff;Douglas C. Palmer;Claudia Wrzesinski

Frequent Co-Authors

Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Zhiya Yu
Zhiya Yu National Institutes of Health
Luca Gattinoni
Luca Gattinoni University of Regensburg
Douglas C. Palmer
Douglas C. Palmer National Institutes of Health
Christopher A. Klebanoff
Christopher A. Klebanoff Memorial Sloan Kettering Cancer Center
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Richard A. Morgan
Richard A. Morgan University of California, Los Angeles
Willem W. Overwijk
Willem W. Overwijk The University of Texas MD Anderson Cancer Center
Mark E. Dudley
Mark E. Dudley Novartis (Switzerland)
Francesco M. Marincola
Francesco M. Marincola National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related online degrees can open up diverse career opportunities in healthcare and research. Many students find accelerated pathways beneficial, such as enrolling in an accelerated fnp program to become a Family Nurse Practitioner, allowing faster entry into advanced clinical roles.

If you do not have a nursing background, starting with online RN programs designed for non nurses can be a great option. These online rn programs for non nurses provide essential training to build a strong foundation in patient care, which complements immunology knowledge.

For those looking for accessible routes into nursing, identifying the easiest accelerated nursing programs can help streamline the education process. These programs typically have flexible admission criteria and compressed timelines.

Additionally, starting a career through accredited lpn programs easy to get into offers a practical entry point into nursing roles, which can later be expanded with further specialization in immunology-related fields.

Best Scientists Citing Nicholas P. Restifo

Trending Scientists

Recently Published Articles